Sodium valproate tablets

This product is an anti-epileptic drug. Its mechanism of action has not been fully elucidated. Experiments show that this product can increase the synthesis of GABA and reduce the degradation of GABA, thereby increasing the concentration of the inhibitory neurotransmitter g-aminobutyric acid (GABA), reducing the excitability of neurons and inhibiting seizures. In electrophysiological experiments, it was found that this product can produce an inhibitory effect on Na channels similar to phenytoin. It is harmful to the liver.

Sodium valproate. Chemical name: 2-sodium valproate Molecular weight: C8H15NaO2

This product is a sugar-coated tablet, which appears white or off-white after removing the sugar coating.

It is mainly used for the treatment of simple or complex absence seizures, myoclonic seizures, and grand mal seizures as a single drug or in combination. It sometimes also has a certain effect on complex partial seizures.

1. Common dosage for adults: 15 mg/kg per day or 600~1200 mg (3-6 tablets) per day, divided into 2~3 doses. Start with 5~10 mg/kg, increase gradually after one week until the attack can be controlled. When the daily dosage exceeds 250 mg, it should be taken in divided doses to reduce gastrointestinal irritation. The maximum daily dosage is no more than 30 mg/kg per day, or 1.8~2.4 g (9-12 tablets) per day. 2. Common dosage for children: The same as that for adults, 20~30 mg/kg per day, divided into 2~3 doses or 15 mg/kg per day, increase by 5~10 mg/kg every other week as needed, until effective or intolerable.

1. Common adverse reactions include diarrhea, indigestion, nausea, vomiting, gastrointestinal spasm, and changes in menstrual cycle; 2. Less common are transient hair loss, constipation, drowsiness, dizziness, fatigue, headache, ataxia, mild tremor, abnormal excitement, restlessness and irritability; 3. Long-term use may occasionally cause pancreatitis and acute liver necrosis; 4. It may cause thrombocytopenia, purpura, bleeding and prolonged bleeding time, and blood tests should be conducted regularly; 5. It may damage liver function, causing elevated serum alkaline phosphatase and aminotransferase, and liver function tests should be conducted after 2 months of use; 6. Occasionally cause allergies; 7. Occasionally cause hearing loss and reversible hearing damage.

Patients with a personal or family history of drug-induced jaundice, liver disease or obvious liver damage are contraindicated. Patients with blood disease, liver disease history, renal damage, or organic encephalopathy should use with caution.

Precautions for children: This product can accumulate in developing bones, so be careful. Precautions for pregnancy and lactation: This drug can pass through the placenta, and there are reports of teratogenicity in animal experiments. Pregnant women should weigh the pros and cons and use it with caution. This product can also be secreted into breast milk, with a concentration of 1-10% of the maternal blood drug. It should be used with caution. Precautions for the elderly: This experiment has not been conducted and there are no reliable references.

(1) Drinking alcohol can increase the sedative effect. (2) When general anesthetics or central nervous system depressants are used in combination with valproic acid, the clinical effect of the former may be more obvious. (3) When used in combination with anticoagulants such as warfarin or heparin, as well as thrombolytics, the risk of bleeding increases. (4) When used in combination with aspirin or dipyridamole, the bleeding time may be prolonged due to reduced platelet aggregation. (5) When used in combination with phenobarbital, the metabolism of the latter slows down and the blood concentration increases, thereby increasing the sedative effect and causing drowsiness. (6) When used in combination with primidone, it may also cause an increase in blood concentration and lead to poisoning. If necessary, the dosage of primidone should be reduced. (7) When used in combination with clonazepam to prevent absence seizures, there have been reports of a few cases where absence seizures were induced. (8) When used in combination with phenytoin, the blood concentrations of both drugs may change due to competition with protein binding. Since the concentration of phenytoin varies greatly, it needs to be measured frequently. However, whether the dose needs to be adjusted depends on the clinical situation and blood concentration. (9) When used in combination with carbamazepine, the induction of liver enzymes will accelerate drug metabolism, which may reduce the blood concentration and half-life of both drugs. Therefore, it is necessary to monitor the blood concentration to determine whether the dosage needs to be adjusted. (10) When used in combination with drugs that are toxic to the liver, there is a potential risk of liver poisoning. Patients with a history of liver disease should have their liver function checked regularly for long-term use. (11) When used in combination with haloperidol, loxapine, maprotiline, monoamine oxidase inhibitors, phenothiazines, thioxanthenes and tricyclic antidepressants, it can increase the inhibition of the central nervous system, lower the startle threshold and the effect of valproic acid, and the dosage must be adjusted in time to control seizures.

Sealed, store in a dry place.

0.2g

30 months.

Hunan Dino Pharmaceutical Co., Ltd.

• Founded in:

  1997-12-02

• Address:

  No. 165, Kangping Road, Liuyang Economic and Technological Development Zone

• Tax NO.:

  91430181183808626X

• Registered Funds:

  17.876059 million yuan

• Website:

  Log in to view

• Email:

  Log in to view